Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics (Nasdaq: FULC) granted inducement stock options to two new employees under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) granted inducement stock options to two new employees under its 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted a total of 55,500 options on an effective date of May 4, 2026 at an exercise price of $7.02 per share. Options have a 10-year term and vest over four years: 25% on the first anniversary, then 6.25% each quarter for the following 12 quarters, subject to continued service.

Argus May 11 session

-0.14% close to close Open Argus

Details

News Market Reaction – FULC

On May 11, the first trading day after this news, FULC closed 0.14% below the previous close.

Data tracked by StockTitan Argus for the May 11 session.

Key Figures

Inducement options granted: 55,500 options Exercise price: $7.02 per share Number of employees: 2 employees +4 more

Inducement options granted

55,500 options

Non-statutory stock options to two new employees under 2022 plan

Exercise price

$7.02 per share

Closing price on grant effective date May 4, 2026

Number of employees

2 employees

Recipients of inducement stock option grants

Option term

10-year term

Duration of granted stock options

Vesting period

4 years

Total vesting timeline for the options

First-year vesting

25% of shares

Cliff vesting on first anniversary of employment

Quarterly vesting rate

6.25% per quarter

Equal installments over 12 quarters after first anniversary

Historical Context

5 past events · Latest: Apr 27

5 events

1. Apr 27

   Earnings and pipeline

   24h Move

   -1.5%

   Q1 2026 results with positive pociredir data and long cash runway.

2. Apr 27

   Board appointment

   24h Move

   -1.5%

   Added experienced biotech executive Josh Lehrer to the board.

3. Apr 20

   Earnings call notice

   24h Move

   -4.2%

   Scheduled Q1 2026 results release and investor conference call.

4. Mar 19

   Strategic partnership

   24h Move

   +1.7%

   Three-year collaboration to improve ED access for sickle cell patients.

5. Mar 06

   Inducement grants

   24h Move

   -2.8%

   Stock options granted to a new employee under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, Nasdaq Listing Rule 5635(c)(4)

2 terms

non-statutory stock options financial

"the company granted non-statutory stock options to two new employees"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

Nasdaq Listing Rule 5635(c)(4) regulatory

"as an inducement material ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees 55,500 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, May 4, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of people with rare hematological disorders. The company’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact: 

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did Fulcrum Therapeutics (FULC) grant on May 4, 2026?

Fulcrum granted a total of 55,500 stock options to two new employees. According to the company, the options were issued as inducement awards under its 2022 Inducement Stock Incentive Plan and tied to new hires entering employment.

What is the exercise price and term for the FULC inducement options?

The options have an exercise price of $7.02 per share and a 10-year term. According to the company, the $7.02 price equals the closing share price on the grant effective date, May 4, 2026.

What is the vesting schedule for the Fulcrum (FULC) inducement grants?

The options vest over four years: 25% on the first anniversary, then 6.25% each quarter for the next 12 quarters. According to the company, vesting is subject to the employees' continued service through each vesting date.

Why did Fulcrum use inducement grants under Nasdaq Rule 5635(c)(4) for FULC hires?

Inducement grants under Nasdaq Rule 5635(c)(4) allow equity awards to recruit key hires outside existing equity plans. According to the company, these options were material inducements for two new employees to enter employment with Fulcrum.

Will the 55,500 FULC options materially dilute existing shareholders?

The press release does not quantify total outstanding shares, so material dilution cannot be determined from the announcement alone. According to the company, 55,500 options were granted; investors must compare that to share count to assess dilution.